• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patentanwaltskanzlei

Patentanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Walter Benjamin Feldheim
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

Amgen patents on cholesterol-lowering drug validated

26. February 2019

U.S. company Amgen has successfully defended two patents related to its cholesterol drug Repatha. The U.S. court in Delaware yesterday confirmed the validity of the patents at the center of the patent dispute with Sanofi and Regeneron.

cholesterol drugAmgen announced yesterday in a press release that the jury of the U.S. court in Delaware decided to confirm the validity of two Amgen patents related to PCSK9 antibodies. The jury pointed out that certain aspects of the packaging have a distinctive and unique appearance and that Amgen’s patents meet the legal requirements for written description and release.

Amgen’s Repatha in more than 60 countries

The controversial patents are significant in connection with Amgen’s cholesterol medication Repatha®. It is a human monoclonal antibody that inhibits the protein conversionase subtilisin/exin type 9 (PCSK9), Amgen describes. Repatha® is approved in more than 60 countries, including the United States, Japan, Canada and all 28 countries that are members of the European Union. Applications in other countries are pending, such as Sanofi SA’s Praluent, also a cholesterol medication. Praluent and Repatha both received US approval to reduce LDL cholesterol in 2015.

California-based Amgen sued Regeneron and Sanofi in 2014, alleging that Praluent infringed patents related to Amgen’s competitor Repatha®. A jury ruled in 2016 that Amgen’s patents related to Repatha were valid. In January 2017, the Delaware judge issued a ban on the sale of Praluent, which was appealed. In October 2017, the US Court of Appeals lifted the ban on selling Praluent and ordered a new trial.

Praluent in the patent dispute before the BPatG

In Germany, the Praluent drug has already been the subject of a lawsuit. The background was an action for a compulsory license on the European patent 2 215 124 (DE 60 2008 042 526) of an U.S. pharmaceutical company. This patent relates to a drug for the treatment of hypercholesterolemia with the active ingredient alirocumab, a monoclonal antibody marketed in the Federal Republic of Germany under the trade name Praluent®. The German Federal Patent Court (BPatG) rejected a patent application in September 2018 ( Application for permission to patent use rejected ).

Update from June 2019: The Federal Supreme Court(BGH) has now confirmed this decision width jugdement of 4 june 2019 BGH X ZB 2/19 Like the BpatG, the BGH takes the view that Sanofi has failed to obtain a contractual licence for Praluent® from Amgen within a reasonable period of time. In addition, the Federal Supreme Court stated that Praluent® and Repatha® were based on the same mechanism of action.

Jury verdict from Delaware – a provisional stage?

Yesterday’s verdict from Delaware in this case is now the latest stage. Regeneron and Sanofi said in a statement that they disagreed with aspects of the ruling and would try to overturn it, Reuters reported.

Do you also need support in protecting your patents or in healthcare and pharmaceutical law?

Our lawyers are experienced in trademark and patent law, national and international law. Please take your chance and contact us.

 

 

 

Sources:

Press Release Amgen On Repatha®

Picture:

geralt / pixabay.com / CCO License

  • share  
  • share 
  • share 
  • share 
  • share 

Category iconHealthcare & Lifesciences,  Patent Law Tag iconAmgen,  Amgen vs. Sanofi,  Praluent,  Regeneron,  Repatha,  Sanofi

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law

Recent Posts

  • What is the public allowed to know? 3. June 2024
  • BPatG: Patent claim of cancer drug on active substance as salt 7. March 2022
  • Grant for European IP Protection: SME Fund 2022 4. March 2022
  • CODE-X vs. Cody’s: Likelihood of confusion in drinks? 25. February 2022

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

7. March 2022
BPatG: Patent claim of cancer drug on active substance as salt

BPatG: Patent claim of cancer drug on active substance as salt

4. March 2022
Grant for European IP Protection: SME Fund 2022

Grant for European IP Protection: SME Fund 2022

22. February 2022
PAP is in force: UPC possible in 2022

PAP is in force: UPC possible in 2022

8. February 2022
Germany: Value in dispute and costs in proceedings

Germany: Value in dispute and costs in proceedings

3. February 2022
PCT application – does the principle of joint applicants apply?

PCT application – does the principle of joint applicants apply?

1. February 2022
Proof of patent infringement by whistleblower

Proof of patent infringement by whistleblower

Contact us or request a call back

+49 (0) 69 / 606 278 – 0
[email protected]
Request a call back

Footer

Contact

Hanauer Landstrasse 287
D – 60314 Frankfurt am Main
Deutschland
+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Office Hours
Moday – Friday:   08:00-18:00

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • xing
  • Email

Newsletter Signup

Newsletter INT

© Meyer-Dulheuer MD Legal Patentanwälte PartG

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

Rückruf INT

Please note: If we deal specifically with your individual case, this is what is known as an initial consultation. In accordance with Section 34 of the Rechtsanwaltsvergütungsgesetz, this incurs one-off costs of 190 euros plus MwSt. We will be happy to assist you in a personal consultation after our telephone call.

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]

Rückruf

Um dieses Angebot nutzen zu können, müssen Sie der Speicherung Ihrer personenbezogenen Daten zustimmen. Wir behandeln diese streng vertraulich und verwenden sie nur zur Kontaktaufnahme mit Ihnen. Mehr dazu lesen Sie in unserer Datenschutzerklärung.

Bitte beachten Sie: Wenn wir uns konkret mit Ihrem Einzelfall befassen, ist dies eine sogenannte Erstberatung. Für eine solche entstehen gemäß § 34 Rechtsanwaltsvergütungsgesetz einmalige Kosten in Höhe von 190 Euro plus MwSt. Gerne helfen wir Ihnen im Anschluss an unser Telefonat in einem persönlichen Beratungsgespräch weiter.